

# OTHER ANTICANCER DRUGS TARGETING DNA AND DNA-ASSOCIATED ENZYMES

## CONTENTS

|   |            |
|---|------------|
| <b>1. DNA intercalation and its consequences</b> .....                                    | <b>274</b> |
| <b>2. Monofunctional intercalating agents</b> .....                                       | <b>276</b> |
| 2.1. Ellipticine and its analogs .....  | 276        |
| 2.2. Actinomycins .....   | 279        |
| 2.3. Fused quinolines .....   | 280        |
| 2.4. Naphthalimides and related compounds .....   | 281        |
| 2.5. Chartreusin, elsamicin A, and related compounds .....                                | 281        |
| 2.6. Other monofunctional intercalating agents .....                                      | 282        |
| <b>3. Bifunctional intercalating agents</b> .....   | <b>282</b> |
| <b>4. Indirect DNA damage by DNA topoisomerase inhibitors</b> .....                       | <b>285</b> |
| 4.1. Topoisomerase I mechanism .....  | 285        |
| 4.2. Topoisomerase II mechanism .....   | 286        |
| <b>5. Specific topoisomerase I inhibitors</b> .....                                       | <b>290</b> |
| 5.1. Camptothecins .....  | 290        |
| 5.2. Non-camptothecin topoisomerase I inhibitors .....                                    | 298        |
| <b>6. Topoisomerase II poisons</b> .....  | <b>301</b> |
| 6.1. Acridine derivatives .....   | 301        |
| 6.2. Anthracyclines and related compounds .....   | 302        |
| 6.3. Non-intercalating topoisomerase II poisons .....                                     | 305        |
| 6.3.1. <i>Etoposide and its analogs</i> .....   | 305        |
| 6.3.2. <i>Salvicine</i> .....   | 308        |
| <b>7. Topoisomerase II catalytic inhibitors</b> .....                                     | <b>309</b> |
| 7.1. Inhibitors of the binding of topoisomerase II to DNA .....                           | 309        |
| 7.1.1. <i>Aclarubicin</i> .....   | 309        |
| 7.1.2. <i>Merbarone</i> .....   | 310        |
| 7.1.3. <i>Bis(dioxopiperazines)</i> .....   | 310        |
| <b>8. Telomerase inhibitors and other anticancer approaches targeting telomeres</b> ..... | <b>311</b> |
| 8.1. G-quadruplex ligands .....   | 313        |
| 8.2. Inhibitors of telomerase reverse transcriptase .....                                 | 316        |
| 8.3. Inhibitors of the RNA domain template .....  | 316        |